A population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disease and type 2 diabetes

Author(s):
Fu, E.L.; Mastrorilli, J.; Bykov, K.; Wexler, D.J.; Cervone, A.; Lin, K.J.; Patorno, E.; Paik, J.M.
Published
2024
Publication type
Article / Letter to editor
chronic kidney diseasedipeptidyl peptidase-4 inhibitorsglucagon-like peptide-1 receptor agonistshyperkalemiasodium-glucose cotransporter-2 inhibitorstype 2 diabetes
Date issued
2024-02-20
Language
English
Is part of
Kidney International (2024), Vol. 105, no. 3, p. 618-628
hdl
1887/4301201
doi
10.1016/j.kint.2023.11.025
URL
https://www.sciencedirect.com/science/article/pii/S0085253823008657?via%3Dihub